(Q61915250)
Statements
A Phase 1, Randomized, Placebo-Controlled, Sequential Parallel Group, Multiple Dose Escalation Trial To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of 4, Once-Weekly Subcutaneous Doses Of PF-04603629 To Subjects With Type 2 Diabetes Mellitus (English)
0 references
April 2008
0 references
September 2008
0 references
42
0 references
18 year
0 references
70 year
0 references